A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
NCT ID: NCT04144049
Last Updated: 2020-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
176 participants
INTERVENTIONAL
2019-09-10
2020-04-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat
NCT05195112
Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
NCT03946592
Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
NCT03224117
An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
NCT05466448
Efficacy and Safety of ZT006 in Overweight and Obese Participants
NCT07230132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MT921
1% or 1.5%, subcutaneously administered at most 50 injections per treatment.
MT921
Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Placebo
Subcutaneously administered at most 50 injections per treatment.
Placebo
Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MT921
Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Placebo
Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects achieving CA-SMFRS and PA-SMFRS score of 2 or 3
* Subjects who voluntarily signed the Informed Consent
Exclusion Criteria
* Subjects with BMI over 35.0kg/m\^2
* Subjects with dysphagia
* Subjects who are allergic or hypersensitive to the investigational product
* Subjects who are pregnant or lactating, or does not agree to use an accepatble form of contraception during the clinical trial.
* Subjects who are otherwise deemed uneligible by the investigator.
19 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medy-Tox
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chung-ang University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT11-KR18SMF203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.